UPCOMING CATALYST MAKES IVERIC BIO A MUST WATCH!
Post# of 22
$ISEE
Iveric Bio, Inc. (NASDAQ: ISEE), is a clinical-stage biopharmaceutical company developing transformative therapies for retinal diseases with significant unmet needs.
The Company’s lead product candidate is Zimura (avacincaptad pegol), a C5 inhibitor that is currently being evaluated in a Phase 3 trial, the topline results from which are expected to be announced in Q3,2022.
Read on to find out more!
https://www.aviseanalytics.com/upcoming-catal...ust-watch/